Published in PLoS One on March 10, 2009
Do ABO blood group antigens hamper the therapeutic efficacy of mesenchymal stromal cells? PLoS One (2014) 0.90
Blood Groups in Infection and Host Susceptibility. Clin Microbiol Rev (2015) 0.88
Molecular ABO phenotyping in cynomolgus macaques using real-time quantitative PCR. Tissue Antigens (2012) 0.83
A fixed-point algorithm for estimating amplification efficiency from a polymerase chain reaction dilution series. BMC Bioinformatics (2014) 0.77
Transcriptional regulation of fucosyltransferase 1 gene expression in colon cancer cells. ScientificWorldJournal (2013) 0.75
Association between ABO Blood Group and Risk of Congenital Heart Disease: A 6-year large cohort study. Sci Rep (2017) 0.75
A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res (1988) 77.80
COBRA: a sensitive and quantitative DNA methylation assay. Nucleic Acids Res (1997) 9.94
Epigenetic remodeling in colorectal cancer results in coordinate gene suppression across an entire chromosome band. Nat Genet (2006) 4.86
Molecular genetic basis of the histo-blood group ABO system. Nature (1990) 4.17
Methylation-sensitive high resolution melting (MS-HRM): a new approach for sensitive and high-throughput assessment of methylation. Nucleic Acids Res (2007) 2.69
Molecular cloning, sequence, and expression of a human GDP-L-fucose:beta-D-galactoside 2-alpha-L-fucosyltransferase cDNA that can form the H blood group antigen. Proc Natl Acad Sci U S A (1990) 2.00
Expression of blood-group antigen A--a favorable prognostic factor in non-small-cell lung cancer. N Engl J Med (1991) 1.52
In-tube DNA methylation profiling by fluorescence melting curve analysis. Clin Chem (2001) 1.51
Sugar-nucleotide donor specificity of histo-blood group A and B transferases is based on amino acid substitutions. J Biol Chem (1990) 1.35
Acute nonlymphocytic leukemia: heterogeneity of stem cell origin. Blood (1981) 1.26
Predictive survival markers in patients with surgically resected non-small cell lung carcinoma. Clin Cancer Res (2000) 1.16
A, B, H antigens in transitional cell tumors of the urinary bladder: correlation with the clinical course. Cancer (1979) 1.12
Loss of red cell A, B, and H antigens is frequent in myeloid malignancies. Blood (2001) 1.09
Detection of virtually all mutations-SSCP (DOVAM-S): a rapid method for mutation scanning with virtually 100% sensitivity. Biotechniques (1999) 1.05
Expression of human histo-blood group ABO genes is dependent upon DNA methylation of the promoter region. J Biol Chem (1999) 1.01
The prognostic impact of blood group-related antigen Lewis Y and the ABH blood groups in resected non-small cell lung cancer. Tumour Biol (2008) 1.00
Review: ABO blood group system--ABH oligosaccharide antigens, anti-A and anti-B, A and B glycosyltransferases, and ABO genes. Immunohematology (2004) 0.99
ABH and Lewis blood group expression in colorectal carcinoma. Cancer Res (1987) 0.98
Correlation of expression of ABH blood group carbohydrate antigens with metastatic potential in human lung carcinomas. Cancer (1993) 0.97
Immunobead RT-PCR: a sensitive method for detection of circulating tumor cells. Biotechniques (1997) 0.96
Loss of blood group A antigen expression in bladder cancer caused by allelic loss and/or methylation of the ABO gene. Lab Invest (2005) 0.96
Genetic and epigenetic alterations of the blood group ABO gene in oral squamous cell carcinoma. Int J Cancer (2004) 0.95
Transcription of human ABO histo-blood group genes is dependent upon binding of transcription factor CBF/NF-Y to minisatellite sequence. J Biol Chem (1997) 0.94
Methylation-sensitive, single-strand conformation analysis (MS-SSCA): A rapid method to screen for and analyze methylation. Hum Mutat (1999) 0.94
Clonal chromosomal abnormalities showing multiple-cell-lineage involvement in acute myeloid leukemia. N Engl J Med (1988) 0.93
Histo-blood group A/B antigen deletion/reduction vs. continuous expression in human tumor cells as correlated with their malignancy. Int J Cancer (1998) 0.88
Screening for and analysis of methylation differences using methylation-sensitive single-strand conformation analysis. Methods (2002) 0.88
Structural variations of blood group A antigens in human normal colon and carcinomas. Cancer Res (1988) 0.86
ABO genotyping by polymerase chain reaction. J Forensic Sci (1992) 0.85
Localization of the human growth arrest-specific gene (GAS1) to chromosome bands 9q21.3-q22, a region frequently deleted in myeloid malignancies. Genomics (1993) 0.85
Scanning by DOVAM-S detects all unique sequence changes in blinded analyses: evidence that the scanning conditions are generic. Biotechniques (2000) 0.84
Expression of A, B, and H blood group antigens in epithelial ovarian cancer: relationship to tumor grade and patient survival. Gynecol Oncol (1996) 0.83
Characterization of the human ABO gene promoter in erythroid cell lineage. Vox Sang (2002) 0.81
Genotypic and phenotypic characterization of the histoblood group ABO(H) in primary bladder tumors. Int J Cancer (1998) 0.80
A rapid and reliable PCR method for genotyping the ABO blood group. Hum Mutat (1993) 0.80
Two A antigens with abnormal serologic properties. Vox Sang (1957) 0.80
Cloning the ABH genes. Transfusion (1990) 0.79
Immunohistochemical expression of ABH/Lewis-related antigens in primary breast carcinomas and metastatic lymph node lesions. Cancer Detect Prev (1998) 0.78
Cloning and regulation of the ABO genes. Transfus Med (2001) 0.78
Blood group antigen expression in dysplasia and adenocarcinoma of the prostate. Am J Surg Pathol (1990) 0.78
Distribution of blood group antigens A, B, H, and I(Ma) in mucus-producing adenocarcinoma of human lung. J Natl Cancer Inst (1984) 0.78
Differences in the two red-cell populations in erythroleukaemia. Lancet (1971) 0.77
Blood group antigens as differentiation and tumor-associated markers in oral epithelium. Proc Finn Dent Soc (1988) 0.77
[A population of erythrocytes with simulated anomaly of phenotypes induced by genes of the ABO locus and adenylate kinase]. Rev Fr Etud Clin Biol (1968) 0.77
Decreased stability of the O allele mRNA transcript of the ABO gene. Blood (1996) 0.77
Acute leukemia with t(1;3)(p36;q21), evolution to t(1;3)(p36;q21), t(14;17)(q32;q21), and loss of red cell A and Le(b) antigens. Cancer Genet Cytogenet (1992) 0.77
Immunophenotype of mitotic cells with clonal chromosome abnormalities demonstrating multilineage involvement in acute myeloid leukemia. Cancer Genet Cytogenet (1993) 0.76
Level of the A, B and H blood group glycosyltransferases in red cell membranes from patients with malignant hemopathies. Rev Fr Transfus Immunohematol (1984) 0.76
Heterogeneic expression of blood group A and H isoantigens in bladder tumors: association with nuclear volume. J Histochem Cytochem (1989) 0.76
A rapid and reliable PCR method for genotyping the ABO blood group. II: A2 and O2 alleles. Hum Mutat (1996) 0.76
[Correlation between DNA methylation of the ABO gene promoter CpG island and leukemia]. Zhongguo Shi Yan Xue Ye Xue Za Zhi (2008) 0.76
Tissue blood-group antigens and prognosis in low stage transitional cell carcinoma of the bladder. J Urol (1978) 0.76
BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J Clin Oncol (2012) 3.86
Empirical array quality weights in the analysis of microarray data. BMC Bioinformatics (2006) 3.54
High resolution melting analysis for the rapid and sensitive detection of mutations in clinical samples: KRAS codon 12 and 13 mutations in non-small cell lung cancer. BMC Cancer (2006) 2.97
Methylation-sensitive high resolution melting (MS-HRM): a new approach for sensitive and high-throughput assessment of methylation. Nucleic Acids Res (2007) 2.69
MicroRNAs: predictors and modifiers of chemo- and radiotherapy in different tumour types. Eur J Cancer (2009) 2.56
High resolution melting analysis for rapid and sensitive EGFR and KRAS mutation detection in formalin fixed paraffin embedded biopsies. BMC Cancer (2008) 2.16
Wnt inhibitory factor 1 is epigenetically silenced in human osteosarcoma, and targeted disruption accelerates osteosarcomagenesis in mice. J Clin Invest (2009) 2.09
Constitutional methylation of the BRCA1 promoter is specifically associated with BRCA1 mutation-associated pathology in early-onset breast cancer. Cancer Prev Res (Phila) (2010) 2.08
Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: preclinical evaluation and results of the phase II DUX study in chemotherapy-refractory, advanced colorectal cancer. J Clin Oncol (2012) 1.95
A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer. J Hematol Oncol (2013) 1.88
Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma. Pigment Cell Melanoma Res (2011) 1.87
Methylation-sensitive high-resolution melting. Nat Protoc (2008) 1.80
Detection of MGMT promoter methylation in normal individuals is strongly associated with the T allele of the rs16906252 MGMT promoter single nucleotide polymorphism. Cancer Prev Res (Phila) (2009) 1.78
A multicenter blinded study to evaluate KRAS mutation testing methodologies in the clinical setting. J Mol Diagn (2009) 1.76
Dramatic reduction of sequence artefacts from DNA isolated from formalin-fixed cancer biopsies by treatment with uracil- DNA glycosylase. Oncotarget (2012) 1.69
High resolution melting for mutation scanning of TP53 exons 5-8. BMC Cancer (2007) 1.65
Reducing sequence artifacts in amplicon-based massively parallel sequencing of formalin-fixed paraffin-embedded DNA by enzymatic depletion of uracil-containing templates. Clin Chem (2013) 1.62
A gene signature identified using a mouse model of androgen receptor-dependent prostate cancer predicts biochemical relapse in human disease. Int J Cancer (2012) 1.60
Sensitive Melting Analysis after Real Time- Methylation Specific PCR (SMART-MSP): high-throughput and probe-free quantitative DNA methylation detection. Nucleic Acids Res (2008) 1.57
Nonequivalent gene expression and copy number alterations in high-grade serous ovarian cancers with BRCA1 and BRCA2 mutations. Clin Cancer Res (2013) 1.54
HER3 and downstream pathways are involved in colonization of brain metastases from breast cancer. Breast Cancer Res (2010) 1.48
The implications of heterogeneous DNA methylation for the accurate quantification of methylation. Epigenomics (2010) 1.45
Galanin mediates the pathogenesis of cerulein-induced acute pancreatitis in the mouse. Pancreas (2010) 1.43
A new approach to primer design for the control of PCR bias in methylation studies. BMC Res Notes (2008) 1.42
Rapid detection of carriers with BRCA1 and BRCA2 mutations using high resolution melting analysis. BMC Cancer (2008) 1.37
BRCA1 promoter methylation in peripheral blood DNA of mutation negative familial breast cancer patients with a BRCA1 tumour phenotype. Breast Cancer Res (2008) 1.30
Distinct clinical and pathological features are associated with the BRAF(T1799A(V600E)) mutation in primary melanoma. J Invest Dermatol (2006) 1.25
The linear no-threshold model does not hold for low-dose ionizing radiation. Radiat Res (2004) 1.25
DNA methylation biomarkers in cancer: progress towards clinical implementation. Expert Rev Mol Diagn (2012) 1.24
Mutations in KIT occur at low frequency in melanomas arising from anatomical sites associated with chronic and intermittent sun exposure. Pigment Cell Melanoma Res (2010) 1.22
BRAF/NRAS wild-type melanomas have a high mutation load correlating with histologic and molecular signatures of UV damage. Clin Cancer Res (2013) 1.18
Limited copy number-high resolution melting (LCN-HRM) enables the detection and identification by sequencing of low level mutations in cancer biopsies. Mol Cancer (2009) 1.17
Mir-148a improves response to chemotherapy in sensitive and resistant oesophageal adenocarcinoma and squamous cell carcinoma cells. J Gastrointest Surg (2011) 1.14
A high-throughput protocol for mutation scanning of the BRCA1 and BRCA2 genes. BMC Cancer (2011) 1.12
BRAF inhibitor-driven tumor proliferation in a KRAS-mutated colon carcinoma is not overcome by MEK1/2 inhibition. J Clin Oncol (2013) 1.12
Assessing combined methylation-sensitive high resolution melting and pyrosequencing for the analysis of heterogeneous DNA methylation. Epigenetics (2011) 1.12
Chemotherapy-induced modification of microRNA expression in esophageal cancer. Oncol Rep (2011) 1.07
Rapid detection of methylation change at H19 in human imprinting disorders using methylation-sensitive high-resolution melting. Hum Mutat (2008) 1.06
Global levels of specific histone modifications and an epigenetic gene signature predict prostate cancer progression and development. Cancer Epidemiol Biomarkers Prev (2010) 1.05
Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines. Pigment Cell Melanoma Res (2014) 1.05
Selective inhibition of proliferation in colorectal carcinoma cell lines expressing mutant APC or activated B-Raf. Int J Cancer (2009) 1.04
Analysing DNA methylation using bisulphite pyrosequencing. Methods Mol Biol (2011) 1.03
Direct genotyping of single nucleotide polymorphisms in methyl metabolism genes using probe-free high-resolution melting analysis. Cancer Epidemiol Biomarkers Prev (2008) 1.01
A multisite blinded study for the detection of BRAF mutations in formalin-fixed, paraffin-embedded malignant melanoma. Sci Rep (2013) 1.01
Increased cancer cell proliferation in prostate cancer patients with high levels of serum folate. Prostate (2011) 1.00
Rapid analysis of heterogeneously methylated DNA using digital methylation-sensitive high resolution melting: application to the CDKN2B (p15) gene. Epigenetics Chromatin (2008) 0.99
DNA methylation profiling of phyllodes and fibroadenoma tumours of the breast. Breast Cancer Res Treat (2010) 0.99
Rarity of AKT1 and AKT3 E17K mutations in squamous cell carcinoma of lung. Cell Cycle (2010) 0.98
MicroRNAs and esophageal cancer--implications for pathogenesis and therapy. Curr Pharm Des (2013) 0.97
Detection of the transforming AKT1 mutation E17K in non-small cell lung cancer by high resolution melting. BMC Res Notes (2008) 0.95
Sensitive detection of KIT D816V in patients with mastocytosis. Clin Chem (2006) 0.95
MicroRNAs, development of Barrett's esophagus, and progression to esophageal adenocarcinoma. World J Gastroenterol (2010) 0.95
Sensitive quantitative analysis of murine LINE1 DNA methylation using high resolution melt analysis. Epigenetics (2012) 0.95
Methylation of the ASC gene promoter is associated with aggressive prostate cancer. Prostate (2006) 0.94
Identification of circulating tumour cells in early stage breast cancer patients using multi marker immunobead RT-PCR. J Hematol Oncol (2009) 0.93
Detection of BRAF mutations in patients with hairy cell leukemia and related lymphoproliferative disorders. Haematologica (2011) 0.93
MicroRNA-143 and -205 expression in neosquamous esophageal epithelium following Argon plasma ablation of Barrett's esophagus. J Gastrointest Surg (2009) 0.92
Variable promoter region CpG island methylation of the putative tumor suppressor gene Connexin 26 in breast cancer. Carcinogenesis (2002) 0.92
Non-linear chromosomal inversion response in prostate after low dose X-radiation exposure. Mutat Res (2006) 0.92
Intratumoral genetic heterogeneity in metastatic melanoma is accompanied by variation in malignant behaviors. BMC Med Genomics (2013) 0.91
Methylation profiling of normal individuals reveals mosaic promoter methylation of cancer-associated genes. Oncotarget (2012) 0.91
Deletion of the glutamate carboxypeptidase II gene in mice reveals a second enzyme activity that hydrolyzes N-acetylaspartylglutamate. J Neurochem (2002) 0.91
The expression of the ubiquitin ligase SIAH2 (seven in absentia homolog 2) is mediated through gene copy number in breast cancer and is associated with a basal-like phenotype and p53 expression. Breast Cancer Res (2011) 0.91
Validation of a primer optimisation matrix to improve the performance of reverse transcription - quantitative real-time PCR assays. BMC Res Notes (2009) 0.90
Clinical and pathological associations of the activating RAC1 P29S mutation in primary cutaneous melanoma. Pigment Cell Melanoma Res (2014) 0.89
Optimisation of the RT-PCR detection of immunomagnetically enriched carcinoma cells. BMC Cancer (2002) 0.89
Differential mechanisms of CDKN2A (p16) alteration in oral tongue squamous cell carcinomas and correlation with patient outcome. Int J Cancer (2014) 0.89
miR-200 family expression is downregulated upon neoplastic progression of Barrett's esophagus. World J Gastroenterol (2011) 0.88
Impact of gastro-esophageal reflux on mucin mRNA expression in the esophageal mucosa. J Gastrointest Surg (2008) 0.88
SGTA: a new player in the molecular co-chaperone game. Horm Cancer (2013) 0.86
Opposing roles of folate in prostate cancer. Urology (2013) 0.86
MiRNAs and their association with locoregional staging and survival following surgery for esophageal carcinoma. Ann Surg Oncol (2010) 0.85
Investigating the potential role of genetic and epigenetic variation of DNA methyltransferase genes in hyperplastic polyposis syndrome. PLoS One (2011) 0.85
Integrated mutation, copy number and expression profiling in resectable non-small cell lung cancer. BMC Cancer (2011) 0.85
Detection of NPM1 exon 12 mutations and FLT3 - internal tandem duplications by high resolution melting analysis in normal karyotype acute myeloid leukemia. J Hematol Oncol (2008) 0.85
Estrogen, male dominance and esophageal adenocarcinoma: is there a link? World J Gastroenterol (2012) 0.84
Circulating Serum Exosomal miRNAs As Potential Biomarkers for Esophageal Adenocarcinoma. J Gastrointest Surg (2015) 0.84
DNA methylation analysis of the HIF-1α prolyl hydroxylase domain genes PHD1, PHD2, PHD3 and the factor inhibiting HIF gene FIH in invasive breast carcinomas. Histopathology (2010) 0.83
Recurrent coiled-coil motifs in NUP98 fusion partners provide a clue to leukemogenesis. Blood (2002) 0.82
Methylation profiling of ductal carcinoma in situ and its relationship to histopathological features. Breast Cancer Res (2014) 0.82
A simple, rapid, and sensitive method for the detection of the JAK2 V617F mutation. Am J Clin Pathol (2007) 0.82
The tripeptide analog feG ameliorates severity of acute pancreatitis in a caerulein mouse model. Am J Physiol Gastrointest Liver Physiol (2008) 0.82
PIK3CA mutations are frequently observed in BRCAX but not BRCA2-associated male breast cancer. Breast Cancer Res (2013) 0.82
Assessing gene-specific methylation using HRM-based analysis. Methods Mol Biol (2011) 0.81
DNA methylation in ductal carcinoma in situ of the breast. Breast Cancer Res (2013) 0.81
A novel duplication polymorphism in the FANCA promoter and its association with breast and ovarian cancer. BMC Cancer (2005) 0.81
Multicenter randomized, open-label phase II trial of sequential erlotinib and gemcitabine compared with gemcitabine monotherapy as first-line therapy in elderly or ECOG PS two patients with advanced NSCLC. Asia Pac J Clin Oncol (2014) 0.81
Aberrant DNA methylation but not mutation of CITED4 is associated with alteration of HIF-regulated genes in breast cancer. Breast Cancer Res Treat (2011) 0.81
Closed-tube PCR methods for locus-specific DNA methylation analysis. Methods Mol Biol (2011) 0.81
The clinical relevance of pathologic subtypes in metastatic lung adenocarcinoma. J Thorac Oncol (2014) 0.80
No evidence for DNA methylation of the ATM promoter CpG island in chronic lymphocytic leukemia. Leuk Lymphoma (2012) 0.80
False negative results from using common PCR reagents. BMC Res Notes (2011) 0.80
Impact of gastro-oesophageal reflux on microRNA expression, location and function. BMC Gastroenterol (2013) 0.79
Characterization of a novel tumorigenic esophageal adenocarcinoma cell line: OANC1. Dig Dis Sci (2014) 0.79
Negative selection of chronic lymphocytic leukaemia cells using a bifunctional rosette-based antibody cocktail. BMC Biotechnol (2008) 0.79
No evidence for promoter region methylation of the succinate dehydrogenase and fumarate hydratase tumour suppressor genes in breast cancer. BMC Res Notes (2009) 0.79
Quantitative threefold allele-specific PCR (QuanTAS-PCR) for highly sensitive JAK2 V617F mutant allele detection. BMC Cancer (2013) 0.79
Characterization of the prostate cancer susceptibility gene KLF6 in human and mouse prostate cancers. Prostate (2012) 0.79
In vivo mutagenic effect of very low dose radiation. Dose Response (2006) 0.78